DNA Repair in Prostate Cancer: Biology and Clinical Implications
Joaquin Mateo1,2, Gunther Boysen1, Christopher E. Barbieri3,4,5, Helen E. Bryant6, Elena Castro7, Pete S. Nelson8,9, David Olmos7,10, Colin C. Pritchard8, Mark A. Rubin4,5,11, Johann S. de Bono1,2
1Division of Cancer Therapeutics and Division of Clinical Studies, The Institute of Cancer Research, London, UK
2Drug Development Unit, The Royal Marsden NHS Foundation Trust, London, UK
3Department of Urology, Weill Cornell Medicine, New York, NY, USA.
4Caryl and Israel Englander Institute for Precision Medicine, New York Presbyterian Hospital-Weill Cornell Medicine. New York, NY, USA
5Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA
6Sheffield Institute for Nucleic Acids, Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
7Prostate Cancer Unit, Spanish National Cancer Research Centre, Madrid, Spain
8Department of Laboratory Medicine, University of Washington, Seattle, WA, USA
9Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
10Medical Oncology Department, CNIO-IBIMA Genitourinary Cancer Unit, Hospital Virgen de la Victoria and Hospital Regional de Malaga, Malaga, Spain
11Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
European Urology
Tập 71
417-425
Thông tin tác giả